San Antonio Breast Cancer Symposium 2024

San Antonio Breast Cancer Symposium 2024
December 10-14, 2024
US - San Antonio, TX

SABCS 2024.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (4)

    Management of Neutropenia and Effectiveness of Sacituzumab Govitecan in Patients With Metastatic Triple-Negative Breast Cancer Treated in Real-World Settings in the United States

    • Author(s): Nanda, R
    • trodelvy
    • Oncology

    Health-Related Quality of Life with Sacituzumab Govitecan versus Treatment of Physician’s Choice in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Meta-Analysis of TROPiCS-02 and EVER-132-002 Trials

    • Author(s): Rugo, H
    • trodelvy
    • Oncology

    Subgroup Analyses from the Phase 3 EVER-132-002 Study of Asian Patients With HR+/HER2– Metastatic Breast Cancer

    • Author(s): Sohn, J
    • trodelvy
    • Oncology

    Quality-adjusted Time Without Symptoms of Disease Progression or Toxicity of Treatment (Q-TWiST) Analysis of Sacituzumab Govitecan vs Chemotherapy in Previously Treated Patients with HR+/HER2– Metastatic Breast Cancer

    • Author(s): Rugo, H
    • trodelvy
    • Oncology